Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma-Reference-Cited by-同舟云学术

Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma

Published:2021-10 Issue: Volume:156 Page:83-92
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Tang Bixia,Mo Jiazhi^ORCID,Yan Xieqiao,Duan Rong,Chi Zhihong,Cui Chuanliang,Si Lu,Kong Yan,Mao Lili,Li Siming,Zhou Li,Lian Bin,Wang Xuan,Bai Xue,Xu Huayan,Li Caili,Dai Jie,Guo Jun,Sheng Xinan

Funder

National Natural Science Foundation of China

Beijing Municipal Science and Technology Commission

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. Mucosal melanoma: new insights and therapeutic options for a unique and aggressive disease;Lerner;Oncology (Williston Park),2017

2. Combatting mucosal melanoma: recent advances and future perspectives;Tyrrell;Melanoma Manag,2018

3. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases;Lyu;J Oral Pathol Med,2016

4. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort;Si;Eur J Canc,2012

5. A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151);Si;Transl Oncol,2019

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consideration on immunotherapy of liver metastases of malignant tumors;World Journal of Gastrointestinal Surgery;2024-08-27

2. Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes;Frontiers in Immunology;2024-07-30

3. Efficacy of axitinib in a US cohort of patients with programmed cell death protein 1–resistant mucosal melanoma;Melanoma Research;2024-06-28

4. Local therapy combined with anti-PD-1 immunotherapy for advanced lung adenocarcinoma: A case report;Journal of Cancer Research and Therapeutics;2024-04

5. Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma;Expert Opinion on Pharmacotherapy;2024-03-23